Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arterioscler Thromb Vasc Biol ; 18(3): 356-61, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9514403

ABSTRACT

Hyperhomocysteinemia is a risk factor for atherosclerosis and thrombosis and is inversely related to plasma folate and vitamin B12 levels. We assessed the effects of vitamin supplementation on plasma homocysteine levels in 89 patients with a history of recurrent venous thrombosis and 227 healthy volunteers. Patients and hyperhomocysteinemic (homocysteine level >16 micromol/L) volunteers were randomized to placebo or high-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine. A subgroup of volunteers without hyperhomocysteinemia was also randomized into three additional regimens of 5 mg folic acid, 0.5 mg folic acid, or 0.4 mg hydroxycobalamin. Before and after the intervention period, blood samples were taken for measurements of homocysteine, folate, cobalamin, and pyridoxal-5'-phosphate levels. Supplementation with high-dose multivitamin preparations normalized plasma homocysteine levels (< or = 16 micromol/L) in 26 of 30 individuals compared with 7 of 30 in the placebo group. Also in normohomocysteinemic subjects, multivitamin supplementation strongly reduced homocysteine levels (median reduction, 30%; range, -22% to 55%). In this subgroup the effect of folic acid alone was similar to that of multivitamin: median reduction, 26%; range, -2% to 52% for 5 mg folic acid and 25%; range, -54% to 40% for 0.5 mg folic acid. Cobalamin supplementation had only a slight effect on homocysteine lowering (median reduction, 10%; range, -21% to 41%). Our study shows that combined vitamin supplementation reduces homocysteine levels effectively in patients with venous thrombosis and in healthy volunteers, either with or without hyperhomocysteinemia. Even supplementation with 0.5 mg of folic acid led to a substantial reduction of blood homocysteine levels.


Subject(s)
Folic Acid/therapeutic use , Homocysteine/blood , Hydroxocobalamin/therapeutic use , Pyridoxine/therapeutic use , Thrombophlebitis/blood , Thrombophlebitis/drug therapy , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Double-Blind Method , Drug Combinations , Female , Folic Acid/administration & dosage , Humans , Hydroxocobalamin/administration & dosage , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Mutation/genetics , Oxidoreductases Acting on CH-NH Group Donors/genetics , Pyridoxine/administration & dosage , Reference Values , Thrombophlebitis/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...